Telo Therapeutics
PublicTelo Therapeutics is now publicly traded
The data on this page reflects Telo Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series A
Dec 21, 2022
Total Funding Raised
$4.71M
Company Overview
Telo Therapeutics is a biotechnology company focused on developing cancer therapeutics aimed at enhancing survival and quality of life for patients with limited treatment options.
Sector
Biotech
AI Layer
Non-AI
Keywords
small molecule telomerase modulatorstelomerase reverse transcriptase (TERT) activatorstelomerase reverse transcriptase (TERT) inhibitorsproprietary small molecule discovery platformtelomere biology drug discoverytherapeutics for pulmonary fibrosistherapeutics for bone marrow failurepreclinical oncology therapeuticstherapeutics for age-related diseasesbiotech drug candidate out-licensingpreclinical biotechnology company
Telo Therapeutics Comparables
Compare Telo Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Rejuvenation Technologies | 57% |
Telo Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 21, 2022 | ||||
| Seed | Jun 21, 2022 |
Telo Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFirmographic Details
HeadquartersBaltimore, Maryland
Employee Range2
Year Founded2015
Last FundingDec 21, 2022
See something wrong or outdated?